Status:
COMPLETED
Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborating Sponsors:
AllerGen NCE Inc.
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related in...
Eligibility Criteria
Inclusion
- Mild stable allergic asthma
- Positive skin-prick test to at least one common aeroallergen
- Positive methacholine challenge
- Positive allergen-induced early- and late-phase airway bronchoconstriction
- General good health
Exclusion
- Lung diseases other than mild allergic asthma
- History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
- Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
- Use of tobacco products within one year starting study or smoking history \>10 pack years
- If female, pregnant or lactating or have positive pregnancy test at screening
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00232999
Start Date
October 1 2005
End Date
January 1 2006
Last Update
November 12 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, McMaster University
Hamilton, Ontario, Canada, L8N 3Z5
2
Centre de cardiology et de pneumologie de l'Universite Laval
Sainte-Foy (Quebec City), Quebec, Canada, G1V 4G5
3
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8